The field of healthcare is rapidly adopting artificial intelligence for enhanced diagnostic and operational efficiency. UCLA leads a $16 million initiative to evaluate AI’s role in breast cancer mammography interpretation through the PRISM Trial, aiming at improving accuracy and screening workflows. Tempus received FDA 510(k) clearance for its RNA-based xR IVD assay to support oncology drug development by detecting gene rearrangements from tumor samples. In parallel, AI systems have been developed for detecting electrophysiological signatures of schizophrenia and bipolar disorder in stem cell-derived brain organoids, advancing neuropsychiatric diagnostics.